Clinical Trials · NCT04707469
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,606
- Start date
- Jan 2021
- Locations
- 228 sites, 15 countries
- Primary endpoint
- Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)